Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–13. doi:https://doi.org/10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroentero. 2017;23(28):5086–96. PMID: 28811705. doi:10.3748/wjg.v23.i28.5086.
   PubMed Web of Science ®Google Scholar
• Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. null. 2016;6(1):29765. doi:10.1038/srep29765.
   Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. Jama. 2021;325(7):669–85. PMID: 33591350. doi:10.1001/jama.2021.0106.
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Colorectal Cancer. National Cancer Institute; Surveillance, Epidemiology, and End Results Program: Maryland (MD); 2012-2018; [ accessed Mar 28] https://seer.cancer.gov/statfacts/html/colorect.html
   Google Scholar
• Coupez D, Hulo P, Touchefeu Y, Bossard C, Bennouna J. Pembrolizumab for the treatment of colorectal cancer. Expert Opin Biol Ther. 2020;20(3):219–26. PMID: 31952453. doi:10.1080/14712598.2020.1718095.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage iii melanoma. N Engl J Med. 2018;378(19):1789–801. doi:10.1056/NEJMoa1802357. PMID: 29658430.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, Stadler WM, Perez-Gracia JL, McNeel DG, Curti B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22(22):5461–71. doi:10.1158/1078-0432.Ccr-15-2839. PMID: 27169994.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28. doi:10.1056/NEJMoa1501824. PMID: 25891174.
   PubMed Web of Science ®Google Scholar
• Sundar R, Cho B-C, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96. doi:10.1177/1758834014567470.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690. PMID: 22658127.
   PubMed Web of Science ®Google Scholar
• Arora SP, Mahalingam D. Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol. 2018;9(1):170–79. PMID: 29564183. doi:10.21037/jgo.2017.06.10.
   PubMed Web of Science ®Google Scholar
• Lu R-M, Hwang Y-C, Liu I-J, Lee C-C, Tsai H-Z, Li H-J, Wu H-C. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z.
   PubMed Web of Science ®Google Scholar
• Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol. 2019;52:42–53. doi:10.1016/j.nbt.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Puca E, Schmitt-Koopmann C, Furter M, Murer P, Probst P, Dihr M, Bajic D, Neri D. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8(+) T cell in an immunocompetent mouse model of colorectal cancer. J Gastrointest Oncol. 2020;11(4):803–11. PMID: 32953162. doi:10.21037/jgo.2020.04.02.
   PubMed Web of Science ®Google Scholar
• Schwegler C, Dorn-Beineke A, Nittka S, Stocking C, Neumaier M. Monoclonal anti-idiotype antibody 6G6.C4 Fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA–transgenic mice. Cancer Res. 2005;65(5):1925–33. doi:10.1158/0008-5472.Can-04-3591.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology. 2017;6(3):e1277306. doi:10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen T-Cell Bispecific Antibody (CEA TCB) for the treatment of solid tumors. Clin Cancer Res. 2016;22(13):3286–97. doi:10.1158/1078-0432.Ccr-15-1696.
   PubMed Web of Science ®Google Scholar
• Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019;177(7):1701–13.e1716. doi:https://doi.org/10.1016/j.cell.2019.04.041.
   PubMed Web of Science ®Google Scholar
• Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, Hughes TA. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108(3):662–67. doi:10.1038/bjc.2012.605.
   PubMed Web of Science ®Google Scholar
• Hammarström S, Baranov V. Is there a role for CEA in innate immunity in the colon? Trends Microbiol. 2001;9(3):119–25. doi:https://doi.org/10.1016/S0966-842X(01)01952-7.
   PubMed Web of Science ®Google Scholar
• Nap M, Mollgard K, Burtin P, Fleuren GJ. Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumor Biol. 1988;9(2–3):145–53. doi:10.1159/000217555.
   PubMedGoogle Scholar
• Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67–81. doi:10.1006/scbi.1998.0119.
   PubMed Web of Science ®Google Scholar
• Rousseau C, Goldenberg DM, Colombié M, Sébille J-C, Meingan P, Ferrer L, Baumgartner P, Cerato E, Masson D, Campone M, et al. Initial clinical results of a novel immuno-PET theranostic probe in human epidermal growth factor receptor 2–negative breast cancer. J Nucl Med. 2020;61(8):1205–11. doi:10.2967/jnumed.119.236000.
   PubMed Web of Science ®Google Scholar
• Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, Lacoeuille F, Drui D, Arlicot N, Goldenberg DM, et al. Clinical results in medullary thyroid carcinoma suggest high potential of pretargeted immuno-PET for tumor imaging and theranostic approaches. Front Med. 2019;6:124. doi:10.3389/fmed.2019.00124.
   Web of Science ®Google Scholar
• Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang C-H, Rossi EA, van der Graaf WT, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109(4):934–42. doi:10.1038/bjc.2013.376.
   PubMed Web of Science ®Google Scholar
• Hao C, Zhang G, Zhang L. Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:213–27.
   PubMed Web of Science ®Google Scholar
• Chester KA, Begent R. Circulating immune complexes (CIC), carcinoembryonic antigen (CEA) and CIC containing CEA as markers for colorectal cancer. Clin Exp Immunol. 1984;58:685.
   PubMed Web of Science ®Google Scholar
• Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with 131 I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14(9):2577–90. doi:10.1245/s10434-006-9328-x.
   PubMed Web of Science ®Google Scholar
• Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35(29):3338. doi:10.1200/JCO.2017.73.9011.
   PubMed Web of Science ®Google Scholar
• Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother. 2009;32(4):341–52. doi:10.1097/CJI.0b013e31819b7c70.
   PubMed Web of Science ®Google Scholar
• Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs. 2014;6(6): 1571–84.
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ, Morse M, McDevitt JT, Ren S, Robbie G, Ryan PC, Soukharev S, Bao H, Denlinger CS. Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas. In: phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas. Am J Clin Oncol. 2016;15(4):345–51.
   Google Scholar
• Moek K, Fiedler W, von Einem J, Verheul H, Seufferlein T, de Groot D, Heinemann V, Kebenko M, Menke-van der Houven van Oordt CW, Ettrich TJ, et al. Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma. Ann Oncol. 2018;29:viii139–40. doi:10.1093/annonc/mdy279.414.
   Web of Science ®Google Scholar
• Murer P, Plüss L, Neri D. A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis. mAbs. 2020;12(1): 1714371.
   PubMed Web of Science ®Google Scholar
• Nadal L, Corbellari R, Villa A, Weiss T, Weller M, Neri D, De Luca R. Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo. mAbs. 2020;12(1): 1836713.
   PubMed Web of Science ®Google Scholar
• Hutmacher C, Volta L, Rinaldi F, Murer P, Myburgh R, Manz MG, Neri D. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. Leuk Res. 2019;84:106178. doi:10.1016/j.leukres.2019.106178.
   PubMed Web of Science ®Google Scholar
• Li Y, Cao H, Jiao Z, Pakala SB, Sirigiri DN, Li W, Kumar R, Mishra L. Carcinoembryonic antigen interacts with TGF-β receptor and inhibits TGF-β signaling in colorectal cancers. Cancer Res. 2010;70(20):8159–68. PMID: 20889724. doi:10.1158/0008-5472.Can-10-1073.
   PubMed Web of Science ®Google Scholar
• Ordoñez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 2000;60(13):3419–24. PMID: 10910050.
   PubMed Web of Science ®Google Scholar
• Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327–34. PMID: 2702691. doi:10.1016/0092-8674(89)90970-7.
   PubMed Web of Science ®Google Scholar
• Taheri M, Saragovi U, Fuks A, Makkerh J, Mort J, Stanners CP. Self Recognition in the Ig Superfamily: iDENTIFICATION of PRECISE SUBDOMAINS in CARCINOEMBRYONIC ANTIGEN REQUIRED for INTERCELLULAR ADHESION*. J Biol Chem. 2000;275(35):26935–43. doi:https://doi.org/10.1016/S0021-9258(19)61463-8.
   PubMed Web of Science ®Google Scholar
• Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis. 2011;28(8):923–32. PMID: 21901530. doi:10.1007/s10585-011-9419-3.
   PubMed Web of Science ®Google Scholar
• Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM, Stanners CP. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin α5β1-fibronectin interaction. J Cell Physiol. 2007;210(3):757–65. PMID: 17167768. doi:10.1002/jcp.20887.
   PubMed Web of Science ®Google Scholar
• Camacho-Leal P, Zhai AB, Stanners CP. A co-clustering model involving α5β1 integrin for the biological effects of GPI-anchored human carcinoembryonic antigen (CEA). J Cell Physiol. 2007;211(3):791–802. PMID: 17286276. doi:10.1002/jcp.20989.
   PubMed Web of Science ®Google Scholar
• Samara RN, Laguinge LM, Jessup JM. Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling. Cancer Res. 2007;67(10):4774–82. PMID: 17510406. doi:10.1158/0008-5472.Can-06-4315.
   PubMed Web of Science ®Google Scholar
• Abdul-Wahid A, Huang EH, Cydzik M, Bolewska-Pedyczak E, Gariépy J. The carcinoembryonic antigen IgV-like N domain plays a critical role in the implantation of metastatic tumor cells. Mol Oncol. 2014;8(2):337–50. PMID: 24388361. doi:10.1016/j.molonc.2013.12.002.
   PubMed Web of Science ®Google Scholar
• Abdul-Wahid A, Huang EH, Lu H, Flanagan J, Mallick AI, Gariépy J. A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo. Int J Cancer. 2012;131(12):2839–51. PMID: 22495743. doi:10.1002/ijc.27582.
   PubMed Web of Science ®Google Scholar
• Orava EW, Abdul-Wahid A, Huang EH, Mallick AI, Gariépy J. Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen. Mol Oncol. 2013;7(4):799–811. PMID: 23656757. doi:10.1016/j.molonc.2013.03.005.
   PubMed Web of Science ®Google Scholar
• Schölzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 2000;156(2):595–605. PMID: 10666389. doi:10.1016/s0002-9440(10)64764-5.
   PubMed Web of Science ®Google Scholar
• Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, Löning T, Wagener C. Cd66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. J Histochem Cytochem. 1996;44(1):35–41. PMID: 8543780. doi:10.1177/44.1.8543780.
   PubMed Web of Science ®Google Scholar
• Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61(12):4750–55. PMID: 11406547.
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250–59. PMID: 21406401. doi:10.1158/0008-5472.Can-10-2277.
   PubMed Web of Science ®Google Scholar
• Bajic D, Chester K, Neri D. An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancerimmunocytokine synergizes with oxaliplatin in cancer models. Mol Cancer Ther. 2020;19(12):2554–63. doi:10.1158/1535-7163.MCT-19-0729.
   PubMed Web of Science ®Google Scholar
• van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen G, Verheul HM, et al. (89)zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: cEA-mediated tumor accumulation and role of IL-2 receptor-binding. Oncotarget. 2018;9(37):24737–49. doi:10.18632/oncotarget.25343. PMID: 29872502.
   PubMedGoogle Scholar
• Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, et al. Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol. 2013;139(3):447–55. doi:10.1007/s00432-012-1327-7. PMID: 23160853.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Spitaleri G, De Pas T, Noberasco C, Giovannoni L, Menssen H, Zardi L, Milani A, Neri D, De Braud F. A dose finding pharmacokinetic study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors. J Clin Oncol. 2007;25(18_suppl):3057–3057. doi:10.1200/jco.2007.25.18_suppl.3057.
   Web of Science ®Google Scholar
• Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med. 2007;5(1):51. PMID: 17953739. doi:10.1186/1479-5876-5-51.
   PubMedGoogle Scholar
• Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99(1):67–74. 10.1182/blood.v99.1.67. PMID: 11756154.
   PubMed Web of Science ®Google Scholar
• Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood. 2006;107(12):4650–57. PMID: 16507779. doi:10.1182/blood-2005-11-4455.
   PubMed Web of Science ®Google Scholar
• Nunez A, Arroyo N, Godoy L, Dutil J. The role of interleukin-12 in breast cancer (CCR6P. 220). J Immunol. 2015;194(1_Supplement):187.187–187.187. doi:10.4049/jimmunol.194.Supp.187.7.
   PubMedGoogle Scholar
• Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood J Am Society Hematol. 1999;94(3):902–08. doi:10.1182/blood.V94.3.902.415k23_902_908.
   Google Scholar
• Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res. 1999;5(12):3983–89. PMID: 10632329.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production. Blood J Am Society Hematol. 1997;90:2541–48.
   Google Scholar
• Neri D. Antibody–cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immunol Res. 2019;7(3):348–54. doi:10.1158/2326-6066.CIR-18-0622.
   PubMed Web of Science ®Google Scholar
• Poli GL, Bianchi C, Virotta G, Bettini A, Moretti R, Trachsel E, Elia G, Giovannoni L, Neri D, Bruno A. Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP Dosimetric PET Study124I-L19SIP PET Study in Patients with Brain Metastasis. Cancer Immunol Res. 2013;1:134–43.
   PubMed Web of Science ®Google Scholar
• Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, Bombardieri E, Grana C, Giovannoni L, Neri D, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med. 2012;53(6):922–27. doi:10.2967/jnumed.111.101006.
   PubMed Web of Science ®Google Scholar
• Chan CHF, Stanners CP. Novel mouse model for carcinoembryonic antigen-based therapy. Mol Ther. 2004;9(6):775–85. doi:https://doi.org/10.1016/j.ymthe.2004.03.009.
   PubMed Web of Science ®Google Scholar
• Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, et al. Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity. Front Oncol. 2020;10:575737. doi:10.3389/fonc.2020.575737.
   PubMed Web of Science ®Google Scholar
• Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496):eaav5989. doi:10.1126/scitranslmed.aav5989.
   PubMed Web of Science ®Google Scholar
• Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365–86. PMID: 33859752. doi:10.7150/thno.58390.
   PubMed Web of Science ®Google Scholar
• Fairhead M, Howarth M. Site-specific biotinylation of purified proteins using BirA. Methods Mol Biol. 2015;216(7):171–84.
   Google Scholar
• Viti F, Nilsson F, Demartis S, Huber A, Neri D. Design and use of phage display libraries for the selection of antibodies and enzymes. Methods Enzymol. 2000;326:480–505. PMID: 11036659. doi:10.1016/s0076-6879(00)26071-0.
   PubMed Web of Science ®Google Scholar
• Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer. 2008;122(11):2405–13. PMID: 18271006. doi:10.1002/ijc.23408.
   PubMed Web of Science ®Google Scholar
• Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 C. Protein Eng Des Sel. 2004;17(4):293–304. PMID: 15115853. doi:10.1093/protein/gzh038.
   PubMed Web of Science ®Google Scholar
• Puca E, Probst P, Stringhini M, Murer P, Pellegrini G, Cazzamalli S, Hutmacher C, Gouyou B, Wulhfard S, Matasci M, et al. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer. 2020;146(9):2518–30. doi:10.1002/ijc.32603. PMID: 31374124.
   PubMed Web of Science ®Google Scholar
• Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C. The structural repertoire of the human V kappa domain. Embo J. 1995;14(18):4628–38. PMID: 7556106. doi:10.1002/j.1460-2075.1995.tb00142.x.
   PubMed Web of Science ®Google Scholar